Comprehensive genomic profiling of Taiwanese triple-negative breast cancer with a large targeted sequencing panel.

ABSTRACT:

Background

Breast cancer is a leading cause of cancer-related deaths in women, particularly those with the triple-negative (TN) phenotype. Although novel therapeutic options are emerging, most are biomarker-driven. This study used comprehensive genomic profiling (CGP) via targeted sequencing to identify actionable alterations in a TN subcohort of the VGH-TAYLOR study.

Methods

The study included patients with either early-stage (defined by first-line surgery or neoadjuvant therapy) or late-stage (defined by relapse or de novo metastatic disease) breast cancer. CGP was performed using the Illumina TruSight Oncology 500 assay. The level of actionability was assessed using the European Society for Medical Oncology (ESMO) Scale of Clinical Actionability of Molecular Targets (ESCA

SUBMITTER: Huang CC 

PROVIDER: S-EPMC12637152 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature